Astellas acquires selected Asian rights to Ironwood's IBS drug
This article was originally published in Scrip
Executive Summary
Astellas has paid $30 million up front for exclusive rights in Japan and most other Asian markets to linaclotide, Ironwood Pharmaceuticals' drug for constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.